HRT and SERMS: The good, the bad...and the lovely?

Trends in Endocrinology and Metabolism

Volumn 13, Issue 8, 2002, Pages 317-318

  Sandberg, Kathryn ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE; BREAST CANCER; CARDIOVASCULAR DISEASE; CONFORMATION; DRUG RECEPTOR BINDING; FEMALE; GENE CONTROL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; UTERUS CANCER; ANIMAL; ARTICLE; ESTROGEN THERAPY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS;

ANIMALS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0036782930     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(02)00674-4     Document Type: Review

References (9)

1. Peto, R. et al. (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355, 1822
2. Writing group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288, 321-333
3. Shiau, A.K. et al. (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9, 359-364
4. Paech, K. et al. (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508-1510
5. Onate, S.A. et al. (1995) Sequence and characterization of a co-activator for the steroid hormaone receptor superfamily. Science 270, 1354-1357
6. Shang, Y. and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468
7. Norris, J.D. et al. (1999) Peptide antagonists of the human estrogen receptor. Science 285, 744-746
8. Zhu, Y. et al. (2002)Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 295, 505-508
9. Xin, H.B. et al. (2002) Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416, 334-337